Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808534 · ClinicalTrials.gov registry record · Phase 2
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01808534 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 5 participants.
The verdict
NCT01808534, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Interventions
- DRUG palifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01808534
The ClinicalTrials.gov registry entry for NCT01808534 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which palifosfamide is the first listed.
NCT01808534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01808534 about?
NCT01808534 is a clinical study titled "Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors". This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
What is the current status of trial NCT01808534?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01808534?
The interventions under investigation include: palifosfamide (DRUG).
Who is sponsoring clinical trial NCT01808534?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.